Propanc Biopharma, Inc.
PPCB
$1.87
-$0.08-4.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14,833.76% | -50.93% | -42.87% | 1.77% | 10.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12,522.64% | -51.29% | -30.30% | 24.00% | 8.98% |
| Operating Income | -12,522.64% | 51.29% | 30.30% | -24.00% | -8.98% |
| Income Before Tax | -10,159.45% | 39.66% | -0.97% | 51.96% | 35.06% |
| Income Tax Expenses | -- | -- | -- | -116.67% | 82.35% |
| Earnings from Continuing Operations | -10,165.29% | 26.39% | -0.97% | 52.06% | 34.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10,165.29% | 26.39% | -0.97% | 52.06% | 34.96% |
| EBIT | -12,522.64% | 51.29% | 30.30% | -24.00% | -8.98% |
| EBITDA | -12,525.62% | 51.30% | 30.30% | -24.18% | -9.07% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |